HC Wainwright & Co. reiterates Buy rating on Cartesian Therapeutics, $25 price target

HC Wainwright & Co. reiterated their Buy rating on Cartesian Therapeutics's stock with a price target of $25.00.The price target implies an upside of 245.3% from the Sep 29 close of $7.24.Key takeaways from the analyst notePromising Clinical Data: Cartesian Therapeutics has demonstrated significant…